This Project Grant award from the National Institute on Minority Health and Health Disparities (NIMHD) under the Minority Health and Health Disparities Research program (CFDA 93.307) will support research to identify and address racial disparities in predictive modeling for survivors of critical illness. The $276,828 award, effective September 30, 2024 through June 30, 2026, will enable the University of Pittsburgh to: Characterize demographic differences in outcomes such as mortality, 90-day...
This federal Project Grant award of $246,776.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel methods for creating and validating polygenic scores (PS) that can predict medication response in African American populations. The goal is to create ancestry-robust PS tools that account for local genetic ancestry context, improving their predictive performance for non-European populations. The...
This Project Grant award of $539,218.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop and validate a prediction model for progression-free survival in patients with myositis-associated interstitial lung disease (ILD). The research aims to identify novel biomarkers and subphenotypes to better understand the clinical and biological heterogeneity of myositis-ILD. The award was granted to The Trustees of the...
This Project Grant award of $194,400 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a multilevel implementation intervention to equitably prescribe evidence-based therapy for hospitalized heart failure patients. The key products or services to be delivered through this funding include: Assessing multilevel variation in equitable guideline-directed medical therapy (GDMT) prescribing during...
This $140,329 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research evaluating racial and ethnic disparities in patient outcomes and intra-arrest resuscitation practices for in-hospital cardiac arrest (IHCA). The key objectives are to: 1) Examine racial and ethnic disparities in time to return of spontaneous circulation (ROSC), survival to hospital discharge, and favorable functional...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $641,544 to the University of North Carolina at Chapel Hill to develop enhanced machine learning tools for complex data evaluation and integration in advancing health outcomes related to heart, lung, blood, and sleep (HLBS) disorders. The project aims to: 1) propose novel machine learning methods for adjusting complex confounding...
This Project Grant from the National Institute for Minority Health and Health Disparities, part of the Department of Health and Human Services National Institutes of Health, provides $769,755 to develop an unbiased machine learning tool for the prediction of acute coronary syndrome. The tool aims to minimize bias in predictions between patient demographic groups, as measured by equal opportunity difference and the Zemel statistic, to ensure machine learning algorithms do not exacerbate...
This Project Grant award of $540,771 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a personalized, socially conscious stroke risk stratification tool for patients with atrial fibrillation (AF). The key objectives are to: 1) Discover new clinical and socioeconomic risk factors for stroke in AF patients by leveraging large datasets including social determinants of health (SDOH) data; 2) Build novel,...
This Project Grant award of $602,358, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to assess the contribution of epigenetics to cardiovascular risk in African American women. The project will identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can contribute to risk prediction assessments. The research will be conducted by the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,564,220 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, on Sep 17, 2024. The grant funds the development of an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system to obtain structural, functional, and metabolic biomarkers of donor lung health. The project aims to use these...
The National Heart Lung and Blood Institute (NHLBI) awarded a $2,260,254 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania to develop, validate, and demonstrate the impact of a novel in-hospital mortality prediction model (MPM) that optimizes fairness across key patient subgroups without sacrificing accuracy.
The project aims to address algorithmic bias in existing MPMs, which have been shown to overestimate mortality for Black patients and underestimate mortality for White patients with acute respiratory failure or sepsis. The University of Pennsylvania will work with Kaiser Permanente Northern California and MedStar Health to develop and validate fairness-informed MPMs using data from over 220,000 patient encounters. The researchers will also conduct focus groups with stakeholders to select the model that best promotes equity and accuracy, test external validity, and quantify the impact of the novel MPM on risk adjustment and resource allocation. Funding for this 5-year project began on September 9, 2024.